文献速递间质性肺疾病肺结节与肺癌

IgG4相关疾病的胸部表现

Thoracic manifestations of IgG4-related disease.
PubMed 文献 · Respirology · 2022-11-27

IgG4相关疾病(IgG4-RD)是一种罕见的系统性纤维炎性疾病,估计年发病率低于1/100,000人。胸部受累在系统性IgG4-RD患者中可达30%,约10%的病例为唯一表现。临床症状非特异,CT表现多样,诊断需谨慎排除恶性肿瘤或血管炎,一线治疗为糖皮质激素。

要点

  • 胸部受累在系统性IgG4-RD中可达30%,约10%为唯一表现。
  • 诊断需结合胸外表现、血清IgG4水平、浆母细胞及病理证据。
  • 糖皮质激素为一线治疗,复发或难治性病例可用利妥昔单抗或改善病情抗风湿药。

核心结论

  • 胸部受累在系统性IgG4-RD中并不少见,诊断需综合临床、影像和病理,治疗以糖皮质激素为主。

研究设计与样本

  • 综述,总结IgG4-RD胸部受累的病理生理、流行病学、诊断和治疗现状。

主要发现

  • 胸部受累在系统性IgG4-RD患者中可达30%,约10%的病例为唯一表现。
  • 临床症状非特异,包括呼吸困难、咳嗽或胸痛。
  • 胸部CT表现异质,主要包括支气管血管周围增厚、结节、磨玻璃影和淋巴结病。
  • 无特异性诊断试验,需寻找胸外表现、血清IgG4升高、浆母细胞及病理证据。

关键数值与推荐

  • IgG4-RD估计年发病率低于1/100,000人。
  • 多克隆IgG4淋巴浆细胞浸润、席纹状纤维化或闭塞性静脉炎对诊断高度提示,但不足以确诊。
  • 糖皮质激素推荐为一线治疗;利妥昔单抗或改善病情抗风湿药可用于复发或罕见激素难治性病例。

临床怎么用

  • 对疑似IgG4-RD胸部受累者,应系统评估胸外表现、血清IgG4、浆母细胞和病理,避免误诊为恶性肿瘤或血管炎。
  • 确诊后首选糖皮质激素治疗,复发或难治性病例考虑利妥昔单抗或改善病情抗风湿药。

局限性

  • 本文为综述,未报告原始研究数据;IgG4-RD胸部受累的流行病学和诊断标准仍需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunoglobulin G4-related disease (IgG4-RD) is a recently described rare systemic fibroinflammatory disease with an estimated incidence of less than 1 in 100,000 persons per year. The disease can affect virtually any organ and is characterized by unifying histopathological findings. Recently, four subgroups of patients have been characterized: hepatobiliary, head and neck, Mikulicz syndrome and retroperitoneal fibrosis, who illustrate the mainly abdominal and ENT tropism of the disease. Yet, thoracic involvement is not uncommon. It can be detected in up to 30% of patients with systemic IgG4-RD and is the exclusive manifestation of the disease in about 10% of cases. Clinical symptoms are nonspecific and may include dyspnoea, cough or chest pain. Chest CT findings are heterogeneous and primarily include peribronchovascular thickening, nodules, ground-glass opacities and lymphadenopathy. There is no specific diagnostic test for IgG4-RD thoracic involvement, which may mimic malignancy or vasculitis. Therefore, a cautious approach is needed to make an accurate diagnosis: a search for extra-thoracic manifestations, elevated serum IgG4 levels, circulating levels of plasmablasts and pathologic evidence of disease is warranted. Although very suggestive, neither the presence of a polyclonal IgG4 lymphoplasmacytic infiltrate, storiform fibrosis or obliterative phlebitis are sufficient to confirm the histological diagnosis. Steroids are recommended as first-line therapy. Rituximab or disease-modifying antirheumatic drugs may be used in relapsed or rare cases of steroid-refractory disease. In this review, we summarize current knowledge regarding the pathophysiology, epidemiology, diagnostic modalities (clinical-biological-imaging-histopathology) and treatment of IgG4-RD thoracic involvement.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Muller R, Ebbo M, Habert P, et al. Thoracic manifestations of IgG4-related disease. Respirology. 2022. PMID: 36437514. doi:10.1111/resp.14422

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。